A cost-of-illness study estimating the direct cost per asthma exacerbation in Turkey

Respiratory Medicine

Volumn 105, Issue 4, 2011, Pages 541-548

  Bavbek, Sevim ^a   Mungan, Dilşad ^a   Türktaş, Haluk ^b   Misirligil, Zeynep ^a   Gemicioǧlu, Bilun ^c  

^a ANKARA UNIVERSITY   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Asthma attack; Asthma control; Asthma cost; Attack severity; Direct cost items; Health economics

Indexed keywords

BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; SALBUTAMOL; STEROID;

ADULT; AGED; ARTICLE; ASTHMA; CONSULTATION; COST OF ILLNESS; DIAGNOSTIC TEST; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; EMERGENCY CARE; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL CARE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; RESOURCE ALLOCATION; RETROSPECTIVE STUDY; TURKEY (REPUBLIC);

ANTI-ASTHMATIC AGENTS; ASTHMA; DIRECT SERVICE COSTS; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TURKEY;

EID: 79952282955     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.10.011     Document Type: Article

References (35)

1. Lane S, Molina J, Plusa T. An international observational prospective study to determine the cost of asthma exacerbations (COAX). Respir Med 2006;100(3):434-50. (Pubitemid 43239877)
2. Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B, Silverman S. Risk factors and costs associated with an asthma attack. Thorax 2000;55:19-24. (Pubitemid 30248774)
3. Sears MR. Epidemiology of asthma exacerbations. J Allergy Clin Immunol 2008;122:662-8 [Review].
4. Ericsson K, Bantje TA, Huber RM, Borg S, Bateman ED. Cost-effectiveness analysis of budesonide/formoterol compared with fluticasone in moderate-persistent asthma. Respir Med 2006;100(4):586-94.
5. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469-78. (Pubitemid 38580764)
6. Jansson SA, Rönmark E, Forsberg B, Löfgren C, Lindberg A, Lundbäck B. The economic consequences of asthma among adults in Sweden. Respir Med 2007;101(11):2263-70. (Pubitemid 47471410)
7. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001;107:3-8.
8. Stock S, Redaelli M, Luengen M, Wendland G, Civello D, Lauterbach KW. Asthma: prevalence and cost of illness. Eur Respir J 2005;25:47-53. (Pubitemid 40207730)
9. Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol 2000;106:493-9.
10. Borderías Clau L, Zabaleta Murguionda M, Riesco Miranda JA, Pellicer Ciscar C, Hernández Hernández JR, Carrillo Díaz T, et al. Cost and management of asthma exacerbations in Spanish hospitals (COAX study in hospital services). Arch Bronconeumol 2005;41(6):313-21. (Pubitemid 41020577)
11. Chapman KR. Impact of 'mild' asthma on health outcomes: findings of a systematic search of the literature. Respir Med 2005;99:1350-62 [Review].
12. Lyseng-Williamson K, Plosker G. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 2003; 21:951-89. (Pubitemid 37222569)
13. Turkish Ministry of Health Chronic Airway Diseases (COPD-Asthma) Prevention and Control Program (2009-2013) Action Plan, Ankara; 2009, pp. 39-41.
14. The global strategy for asthma management and prevention, global initiative for asthma (GINA) 2007. Available from: http://www.ginasthma.org.
15. Sekerel BE, Gemicioglu B, Soriano JB. Asthma insights and reality in Turkey (AIRET) study. Respir Med 2006;100:1850-4. (Pubitemid 44375491)
16. Türktaş H, Mungan D, Uysal A, Oguzulgen K. Determinants of asthma control in tertiary level in Turkey: a cross-sectional multicenter survey. J Asthma 2010;47(5):557-62.
17. Wenzel SE, Busse WW. The national heart, lung, and blood Institute's severe asthma research program. Severe asthma: lessons from the severe asthma research program. J Allergy Clin Immunol 2007;119:14-21.
18. Bavbek S, Misirligil Z, Study Group. A breath for health: an exploratory study in severe asthma patients in Turkey. Allergy 2008;63(9):1218-27.
19. Bavbek S, Celik G, Ediger D, Mungan D, Sin B, Demirel YS, et al. Severity and associated risk factors in adult asthmatic patients in Turkey. Ann Allergy Asthma Immunol 2000;85:134-9. (Pubitemid 30659538)
20. Celik GE, Bavbek S, Paşaoǧlu G, Mungan D, Abadoǧlu O, Harmanci E, Misirligil Z. Direct medical cost of asthma in Ankara, Turkey. Respiration 2004;71(6):587-93. (Pubitemid 40091431)
21. Rutten van-Molken MP, Feenstra TL. The burden of asthma and chronic obstructive pulmonary disease: data from the Netherlands. Pharmacoeconomics 2001;19(S2):1-6.
22. Cisternas MG, Blanc PD, Yen IH, Katz PP, Earnest G, Eisner MD, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003;111:1212-8. (Pubitemid 36683672)
23. Oostenbrink JB, Rutten-van Mölken MP. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 2004; 98(9):883-91. (Pubitemid 39069339)
24. Moore WC, Peters SP. Severe asthma: an overview. J Allergy Clin Immunol 2006;117(3):487-94.
25. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prütz C, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96(9):700-8.
26. Serinken M, Dursunoǧlu N, Cimrin A. Therapy costs of adult patients admitting to emergency unit of a university hospital with asthma acute attack. Tuberk Toraks 2009;57(2):198-204.
27. Pawar V, Smith MJ. Asthma-related healthcare services utilization by African-Americans enrolled in West Virginia Medicaid. Respir Med 2006;100(9):1579-87. (Pubitemid 44089359)
28. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004;114(1):40-7. (Pubitemid 39022491)
29. Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet 1999;353(9150):364-9. (Pubitemid 29088164)
30. Kips JC, Pauwels RA. Asthma control: where do we fail? Eur Respir J 2000;16(5):797-8.
31. Sekerel BE, Saraclar Y, Ones U, Guneser S, Akcakaya N, Tanac R. On behalf of the Turkish national allergy and clinical immunology society. Childhood asthma perception in Turkey under real-life environment (CAPTURE) study. Pediatr Allergy Immunol 2001;12:266-73.
32. Civelek E, Sekerel BE. Management of childhood asthma: Physicians' perspective in Turkey. Pediatr Allergy Immunol 2004;15:372-5. (Pubitemid 39093496)
33. Haselkorn T, Fish JE, Zeiger RS, Szefler SJ, Miller DP, Chipps BE, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the expert panel report 3 guidelines, increases risk for future severe asthma exacerbations in the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. J Allergy Clin Immunol 2009;124(5):895-902.
34. Bateman ED. Using clinical measures of disease control to reduce the burden of asthma. Pharmacoeconomics 2001;19 (Suppl. 2):7-12.
35. Aydin O, Erkekol FO, Turan V, Yildiz B, Elmas TS, Sönmez N, et al. Have the factors affecting the direct cost of asthma changed in 8 years? Asthma Allergy Immunol 2009;7:118-25 [in Turkish].